A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Status:
Unknown status
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, Phase II study of intravenous (IV) SHR-1210 at 200mg,q2w
in combination with Apatinib at two dose levels in subjects with locally advanced or
metastatic non-small cell lung cancer (NSCLC).
The study is composed of two parts. Part 1 of the study will determine the safety
,tolerability and pharmacokinetics of SHR-1210 in combination with Apatinib.
Part 2 includes a randomized comparison of Apatinib 250mg/d or 500mg/d plus SHR-1210 .
Subject's tumors will be screened at baseline for EGFR mutations, EML4-ALK translocation, and
PD-L1 expression.But positive tumor PD-L1 expression will not be required for enrollment.